-
July 18, 2012
Johnson & Johnson has kicked off the US reporting season by posting a 49.3% fall in earnings for the second quarter, hit by charges, and healthy sales of new products, notably the prostate cancer drug Zytiga
Full story
-
April 18, 2012
Kicking off the US reporting season, Johnson & Johnson has posted a 12.5% rise in earnings for the first quarter, helped by sales of new products, the most eye-catching being the prostate cancer drug Zytiga
Full story
-
January 25, 2012
Kicking off the reporting season for the majors, Johnson & Johnson has posted a 88.8% slump in earnings for the fourth quarter, battered by charges, including litigation and product-liability related items
Full story
-
October 19, 2011
Johnson & Johnson has posted a solid set of figures for the third quarter, with sales of pharmaceuticals outside the USA making up for declines at home
Full story
-
October 17, 2011
A US jury has decreed that Johnson & Johnson is not responsible for tendon damage suffered by two men who took the healthcare giant's former blockbuster antibiotic Levaquin
Full story
-
June 21, 2011
Having just won a court case concerning the risks of taking Levaquin, Johnson & Johnson will now have to compete with a number of generics of its big-selling antibiotic in the USA
Full story